2009, ISBN: 9787530439463

Pasta blanda, Pasta dura

paperback. New. Ship out in 2 business day, And Fast shipping, Free Tracking number will be provided after the shipment.Pub Date: 2008 Publisher: Tsinghua University Press book titles: h… Más…

paperback. New. Ship out in 2 business day, And Fast shipping, Free Tracking number will be provided after the shipment.Pub Date: 2008 Publisher: Tsinghua University Press book titles: heart failure Integrative Therapeutics Ages: Book pricing: the the 100.00 yuan book number: B001ISJSZG book author: YUAN Congress Press: Tsinghua University Press. ISBN Number: 9787302155287 Publication Date: October 1. 2008. the first edition of the book Pages: 691 books open: 16 Dimensions Weight: 26x18.2x3.8; 1300 g Description heart failure Integrative Therapeutics practical. the book describes the treatment of heart failure in recent years. I would recommend this as a reference to colleagues. apply to work in cardiovascular surgery. Division of Emergency Medicine and Intensive monitoring clinicians. The book is compiled by a group of young scholars and experts from academic serious. serious attitude. the spirit of the work enthusiasm. so I gladly willing book's preface. The publication of the book will be of Chinese and Western medicine cardiovascular disease. especially heart failure clinical research and teaching work make an important contribution. Finally. expect the author of the book on the basis of the early studies of heart failure to forge ahead. give full play to the advantages of the combination of Chinese and Western. to make greater contributions to human health. Editor's Choice heart failure Integrative Therapeutics published by Tsinghua University Press. About the author Wu Hong Kim. Beijing University of Traditional Chinese subsidiary of the combination of Chinese and Western medicine hospital director. chief physician. professor and doctoral supervisor. director of the World Federation of Pharmaceutical Pharmaceutical Society of Cardiovascular Professional Committee. China in Integrative Medicine Society. the National Pharmaceutical Association of Higher Education clinical Education Research Association. the China Gerontological Society abundance of any member. vice of the Medical Research Council. the National Natural Science Foundation of peer review experts. the vice president of the Beijing Institute of Integrative Medicine. Beijing Institute of Integrative Medicine. vice chairman of the Youth Committee. China Chinese and Western medicine clinical journal Medical Review magazine editor. key disciplines of Traditional Chinese Medicine in Beijing - Integrative cardiovascular medicine entancement. Chinese and Western medicine is mainly engaged in basic and clinical research and treatment of cardiovascular diseases. the combination of Chinese traditional medicine and modern biological techniques. combined treatment method for the in-depth study of the pathogenesis of coronary heart disease. heart failure. and in Western medicine. Applying genomics technologies to study the influence of tetramethylpyrazine on the gene expression profiles of human endothelial cells. and the application of proteomics technologies to study the change of heart and kidney yang heart failure related protein. these findings reveal the essence of TCM. Chinese medicine treatment of heart The mechanism of vascular diseases and cardiovascular drug development has important significance. Develop treatments for coronary heart disease. heart failure Traditional Chinese Drug Research - effort Kang particles. has completed the production process. quality control. acute toxicity. chronic toxicity and pharmacodynamic study. Has presided over the National Natural Science Foundation. the State Administration of Traditional medicine science technology research fund. the capital of Medical Development Scientific Research Fund. Beijing Medical Health Technology focus on support for the project. the Beijing Traditional Chinese Medicine Technology project significant special Beijing Chinese medicine research focused discipline projects and other research topics. Editor ((hypertension Chinese and Western medicine clinical disposal strategy medicine monographs 2. supervised the two books and more than 40 articles published research papers. Yuan Congress. Qingdao University Affiliated Yantai Yuhuangding Hospital Chief Physician. Professor. Ph.D.. has long been engaged in Department of Cardiology. clinical and interventional treatment work. mainly engaged in the study of the pathogenesis of coronary heart disease heart failure in recent years carried out a systematic study of mast cells in acute myocardial infarction myocardial fibrosis in the role as well as the effect of the intervention of the Chinese medicine. has been published more than 30 research papers. the Academic of l. the senate two books. to participate in the national 863 project a catalog articles Western medicine. Chapter 1. the etiology and epidemiology of heart failure on the first section of heart failure etiology Molecular Biology Section III Section II of Section I of Chapter 2. Section II of the epidemiological studies of heart failure and incentives pathophysiology of heart failure heart failure decompensation and decompensated failure myocardial failure myocardial adrenaline Section I Section II of the clinical manifestations of heart failure in the diagnosis of heart failure in the role of the change Section IV cytokine receptor signaling and reactive oxygen species in the heart failure section V. reduced myocardial systolic and diastolic function mechanisms Chapter 3 Section III of the chest radiograph of heart failure heart failure echocardiography Figure check Section IV heart attack nuclear exercise testing of medical examination Section V Section VI Determination of cardiac catheterization and hemodynamic Section VII of heart failure laboratory tests the drug treatment of heart failure diagnostic section IX of the of Section VIII diastolic heart failure heart failure diagnosis process. standards and classification in Chapter 4 Section II of Section I of diuretics vasodilators the third quarter of inotropic drugs ganglion hormone antagonist Section 5 Other new drugs Chapter 5 of heart failure in the third quarter of the adverse effects of conventional right ventricular apical pacing right ventricular pacing in patients with the progress of the first section of cardiac physiologic pacing Section II bifocal mechanism for the third quarter of mechanical ventilation pacing Section IV cardiac resynchronization therapy Chapter 6 mechanical ventilation in heart failure in the application of section I of obstructive sleep apnea syndrome and cardiovascular disease Section II mechanical ventilation in the treatment of heart failure Section III of Chapter 7 of heart failure surgical treatment of the theoretical basis of the first surgical treatment of heart failure in section II of the implementation of the clinical application of the fourth quarter of mechanical ventilation simple cardiac surgical techniques improve myocardial contractile function for the treatment of cardiac morphology and component repair heart failure heart surgery in the fourth quarter the surgical treatment of acute heart failure technology section V of the unity of the surgical and medical treatment of heart failure stem cell treatment of heart failure in Chapter 8 Section 1 Stem Cell Overview Section 2 stem cell therapy for myocardial infarction and effort Section IV of the failure of the third quarter exist Development and Prospect of Section III of Chapter 9 of heart failure gene therapy Section 1 Introduction to gene therapy Section II cardiac hypertrophy and failure of molecular biology and cell biology of heart failure change Section III Section II rehabilitation of heart failure gene therapy Chapter 10 Section 1 with chronic heart failure. abnormal peripheral mechanism of chronic heart failure treatment mode exercise training for patients with chronic heart failure treatment Chapter 11 Acute Heart Failure The first section of acute left ventricular failure Section II acute right heart failure Chapter 12 diastolic ventricular diastolic function in heart failure the first section and influencing factors of Section II of diastolic heart failure etiology and pathophysiology of the third quarter of diastolic heart failure diagnosis difficult to Section III of the fourth quarter of diastolic heart failure treatment prognosis of diastolic heart failure Section V Chapter 13. the diagnosis of refractory heart failure and refractory heart failure (1) Section 2 treatment of refractory heart failure Chapter 15 Section II heart failure of Chapter 14 of heart failure in the treatment of heart failure complications of treatment of evidence-based medical research Section 1 Introduction to evidence-based medicine evidence-based medical research with chronic congestive heart failure due to coronary artery disease first section of acute myocardial infarction complicated effort Failure Section II Section II of Chapter 16 section I of the hypertensive heart failure etiology of ischemic cardiomyopathy with heart failure pathology and pathophysiology of Section III in section IV of the clinical manifestations of laboratory tests and other examinations Section V diagnosis of the first six treatment Chapter 17 valvular heart disease heart failure the first section mitral stenosis Section II mitral stenosis aortic regurgitation Section III Section IV aortic regurgitation Section V tricuspid stenosis sixth section the tricuspid regurgitation Section VII pulmonary valve stenosis in section VIII of the pulmonary valve regurgitation Chapter 18 of viral myocarditis myocarditis heart failure (1) Section II Section III of myocarditis caused by other pathogens and immune abnormalities related to heart disease cardiomyopathy heart failure (1) dilated cardiomyopathy Chapter 19. section II. section III of hypertrophic cardiomyopathy restrictive cardiomyopathy caused by the arrhythmia type right ventricular cardiomyopathy Section IV of Chapter 20 of chronic pulmonary heart failure Section II of the first section of the characteristics of chronic pulmonary heart disease. heart failure treatment of chronic pulmonary heart disease. heart failure Chapter 21 failure and renal insufficiency in heart failure kidney 1 Section II due to heart failure Section III of the diagnosis of kidney damage in heart failure combined treatment of the fourth quarter of renal insufficiency. renal failure complicated by heart failure Chapter 22 endocrine and metabolic diseases and heart failure Section I the Diabetes Section II thyroid function in section III of hyperthyroidism thyroid function The first section of Chapter 23 of heart failure and perinatal hypothyroidism Section IV acromegaly Overview Chapter 24 of Section II of the clinical diagnosis and differential diagnosis of Section III treatment of the fourth quarter and pregnancy are directly related to heart failure heart failure with the oral diseases Section 1 Overview Section II oral bacterial infection and heart failure section I of Chapter 25 of heart failure and brain heart and brain syndrome first tooth the third quarter with Section IV heart failure obstructive sleep apnea syndrome and heart failure two brain-heart syndrome Chapter 27 of perioperative heart failure and anesthesia Section I of Chapter 26 of heart failure and anemia first section of anemia. heart disease Section II chronic heart failure in the anemia of perioperative heart failure deal with the fourth quarter of Section II left ventricular failure the Section III right heart failure patients perioperative management of patients with perioperative anesthesia Wai-operative heart failure patients progress Chapter 28 Chapter 29 characteristics of pediatric heart failure in elderly heart failure is characterized by morphological and physiological features of the first section elderly cardiovascular changes. sect treatment of elderly heart failure in elderly heart failure clinical features of Section III of Chapter 30 of heart failure and arrhythmia the first section arrhythmia caused effort Section II of the first nursing assessment and diagnosis of failure Section II heart failure associated with arrhythmias Chapter 31 of heart failure nursing care Chapter 32 of heart failure. heart failure prognosis - 11 Section 1 clinical factors on prognosis Section V impact hemodynamics and cardiac function factors in section II of Section III complications and comorbidities on the prognosis of the fourth quarter ECG and electrophysiological check neuroendocrine factors on the prognosis of Section VI Chapter 33 heart failure animal model of the first cardiac stress changes induced heart failure model the second myocardial ischemia induced heart failure model induced heart failure model in the third quarter of rapid ventricular pacing Act Section IV drug induced heart failure model in section V vitro Heart Failure Model Section VI bacterial or viral myocarditis. heart failure model in section VII diastolic heart failure model of Section VIII genetic type and transgenic heart failure model in section IX of Integrative Medicine section X of the production of animal models of heart failure in heart failure model Chinese medicine. the physiological function of the heart in the first section of the articles in Chapter 34 of the Integrative Medicine on the understanding of the physiological function of the heart medicine Section II of the heart and other organs of the relationship of standards and evaluation next Chapter 35 of heart failure in Section I of the medical origins and development of heart failure disease name in the medical understanding of Section II of heart failure in medical understanding of the etiology and pathogenesis of the third quarter of section IV of waiting for heart failure certificate in medical knowledge in heart failure treatment Chapter 36. in the medical understanding of the diagnosis and treatment of heart failure and other related diseases section I. section II of coronary heart myocarditis heart failure the third quarter cardiomyopathy heart failure with Section IV pulmonary heart disease. heart failure Section V hypertensive heart failure diabetic heart disease and heart failure in Section VI Section VII hyperthyroidism heart disease and heart failure in section VIII of hypothyroid heart disease and heart failure of Section IX chronic kidney failure and heart failure in section X effort the TCM Syndrome Law of failure and encephalopathy Section XI of heart failure and Perinatal Section XII Chapter 37 of heart failure with oral disease heart failure (1) Syndrome with Resolution Section II Differential Treatment of the third quarter effort the single herbs failure syndromes fourth quarter dialectical law changes in Section V of the objective indicators of heart failure syndrome type of Chapter 38 of Section I of the traditional Chinese medicine to treat heart failure heart failure treatment in section II heart failure Compound treatment of third Chapter 40 of Section II of Chapter 39 of heart fa, hardcover. New. Ship out in 2 business day, And Fast shipping, Free Tracking number will be provided after the shipment.Pub Date: 2009 Pages: 507 Publisher: Beijing Science and Technology Press Information title: rectal Original Price: $ 120.00: Neg Press: Beijing Science and Technology Press Publication Date: January 1. 2009 ISBN: 9787530439463 Number of words: Page: 507 Edition: 1st Edition Binding: Hardcover Folio: 16 commodity identification: asinB001QDT9KW Editor's Choice cancer Beijing Science and Technology Publishing House. Abstract No Table of Contents Chapter Section I of the rectum and anal canal anatomy and outside the scientific significance of the gross anatomy of the rectum and anal canal Section III of Section II of the blood vessels of the rectum and anal canal and surgical significance of the rectum and anal canal lymphatic system and lymph node metastasis in the fourth quarter of the rectum and anal canal nerve etiology and pathogenesis of Section 1 of Chapter II rectal cancer epidemiology risk factors for rectal cancer incidence trend Section II Section III rectal cancer basic clinical research focus of the first section of the Chapter of the pathogenesis of the fourth quarter with rectal cancer. cancer development related genes Section V protein patterns and gene profiling studies progress cancer lymph node metastasis in colorectal cancer mesorectal Section II rectal pelvic wall lymph node metastasis law Section III rectal cancer sentinel lymph nodes Research Section IV cancer lymph node micrometastases Section V chemoradiotherapy sensitive predictor Section VI cancer prognosis assessment indicators Section I of the chapter rectal cancer-related genetic diseases knot rectum polyps disease Section II hereditary nonpolyposis colorectal to Section III the MYH the relevant polyposis Chapter cancer diagnosis and pathological staging Section I rectal cancer The clinical manifestations and diagnosis of second cancer clinical pathology section III of clinical and pathological staging the Chapter rectal surgery preparation before the first section surgery generally ready to Section 2 preoperative nutritional assessment and support section III rectal cancer Chapter 8 of the accelerated rehabilitation program for bowel preparation before surgery the fourth quarter of surgical risk assessment methods Chapter VII of rectal perioperative rectal cancer surgery and controversies Section I Overview Chapter IX neoadjuvant treatment of rectal cancer Section II rectal cancer and indications neoadjuvant radiotherapy Section III neoadjuvant chemoradiotherapy the fourth quarter of neoadjuvant treatment and processing joint cancer of the open surgery Section 1 of Chapter cancer abdominal perineal resection (Miles Section II of the surgery) low rectal resection (Dixon surgery) Section III full mesorectal resection of the fourth quarter section VII of the pelvic dissection sphincterotomy Section V Hartmann Surgery Section VI rectal cancer resection 10th - Festival the low rectal cylindrical abdominoperineal resection the surgery section VIII. by sacral resection for rectal cancer section IX. rectal sphincter resection of section X of rectal sphincter ways rectal anus colon pull joint resection first reserved the eleven chapters rectal laparoscopic surgery for the first section of laparoscopic surgical treatment of rectal cancer development history section II. section III of the TME surgery laparoscopic rectal laparoscopic Miles' operation for rectal cancer the fourth quarter laparoscopic rectal sphincter resection the stenting for Section III rectal cancer treatment of the first section rectal surgery XII rectal cancer with acute intestinal obstruction with acute intestinal obstruction in section II of the surgical treatment of rectal cancer with acute intestinal obstruction with acute intestinal obstruction catheter Less Chapter XIII of the pressure treatment of refractory colorectal cancer surgery complications and their prevention and control presacral bleeding Section II rectal cancer resection anastomosis leakage Section I rectal cancer surgery in the third quarter of anastomotic stenosis Section IV rectovaginal fistula Section V of postoperative complications of the ileum. the colon pouch after Section VI rectal surgery manufacturing the mouth beside hernia Section VII Miles operation of section VIII of the radioactive intestinal fistula and perineal wound healing factors and prevention Chapter 14 mechanical suture equipment used in its prevention and treatment the Chapter XV carcinoembryonic antigen and radioimmunoimaging mediated cancer diagnosis and treatment of Chapter XVI of rectal postoperative adjuvant therapy for the first section of rectal cancer after radiation therapy the care and treatment of perioperative Section II Section II Section III rectal cancer after chemotherapy molecular targeted therapy treatment first section of the Chapter XVII intestinal stoma care and its complications cancer enterostomy enterostomy rehabilitation period after cancer surgery care Chapter XVIII of the follow-up and monitoring of Chapter XIX cancer after surgery anal sexual function. urinary function and quality of life Section 1 cancer anal function after surgery evaluation and rehabilitation of surgery after sexual function and urinary function evaluation and rehabilitation Section II Section III rectal cancer surgery after treatment of the first section of the status quo and evaluation of the quality of life Chapter cancer recurrence and metastasis of cancer recurrence and the section II of the transfer of the concept and related factors of local recurrence of cancer treatment section III colorectal liver metastases diagnosis and surgical treatment of chapter 21 of the twenty-second chapter of the anal canal cancer cancer screening and chemoprevention Chapter cancer at home and abroad guiding handle tertiary prevention of cancer the fourth quarter of the third quarter in the first section cancer screening Section II rectal tumors found by screening cancer chemopreventive the File file a United States rectal treatment of clinical guidelines (revised 2005) documents two laparoscopic radical the operative guidance document III lower rectal surgical treatment specification file four oncology clinical the guide-V.1.2008 file five British colorectal liver metastases treatment guidelines file six endoscope in colon cancer diagnosis. staging and treatment-ASGE (American Society for Gastrointestinal Endoscopy) guidance documents and seven foreign societies and organizations recommended colorectal cancer screening guidelines list selected file eight Chinese people embodiment of hereditary colorectal cancer screening standards introduced Neg. male. born in 1965. Capital Medical University. Beijing Chaoyang Hospital. director of the Department of General Surgery. the chief physician. professor and doctoral supervisor. the incumbent Sciences Branch of the Chinese Medical Association junction the anorectal surgery group deputy head of the Surgery Branch of the National Committee of the Chinese Medical Association. Journal of General Surgery Magazine and Journal of Gastrointestinal Surgery. Chinese Journal of Surgery . China Surgery . Chinese Journal of Experimental Surgery magazine editorial. China clinicians Editorial Board vice chairman. Cancer Research Managing Editor. Jiu San Society of the Beijing Municipal Committee. Graduated from Beijing Medical University and received his MD in 1992. 1997-1998 as a visiting scholar at the University of Oxford. the Wellcome trust center study of human genetic diseases. tumor molecular genetics .1998-2004 Surgical Research Office of Peking University First Hospital. Peking University First Hospital. deputy director of Institute of Clinical Medicine . Professor. Chief Physician. Professor. In May 2004. has served as director of the Department of General Surgery. Beijing Chaoyang Hospital. Capital Medical University. Professor Wang Zhenjun specializes in gastrointestinal tumors and anorectal benign disease treatment. particularly in gastric cancer. colorectal cancer. low rectal cancer. anal fistula and haemorrhoids treatment successes. a leading domestic position: (1) in the country within the first to carry out rectal sphincter excision for low rectal sphincter preserving surgery. and innovative design to retain part of the dentate line of the internal sphincter resection. (2) in the country to carry out the earlier diagnosis and treatment of tumors of the gastrointestinal hereditary disease genes and hereditary non-polyposis colorectal cancer. Peutz-Jeghers disease detection. found a new gene mutation point. summed up the clinical pathology and gene mutation characteristics. diagnostic points of these diseases. treatment principles. (3) the application of innovative allogeneic acellular dermal matrix material filling the treatment of simple and complex anal fistula. (4) the mechanism of the hemorrhoid carried out in-depth research. (5) and low rectal columnar abdominal perineal resection first in the country. As l Project Leader. has undertaken the National Youth 863 plan one. more than four. the National Ministry of Education issues two. the National Natural Science Foundation of more than 10 provincial and ministerial research projects. 2002 by the Beijing Municipal Science and Technology Progress Award. 2003 as Beijing's united front system to SARS Prevention advanced personal selected Beijing New Century Talents Project in 2008. Senate Surgery (English) Medical monograph seven core magazines at home and abroad. has published more than 100 academic articles. J Pathol. J cancer . J Med Genet. Am I Pathol and Dis Colon Rectum SCI magazine included more than thirty. 9 invention patents. Abstracts October 2006. Nadauld LD by the presence of a mutation in the APC gene in zebrafish cells discovered a new function of the APC gene. The study confirmed that the normal cells of the human and zebrafish. APC gene transcription repressor the collaborative molecular C_ end-binding protein 1 (c-terminal binding proteinl. CTBPl) mark and degradation. which control CTBPl number of molecules. APC mutant zebrafish tissues. CTBPl levels were significantly increased. The study further found that adenomas in familial polyposis. CTBPl the expression was significantly higher than the normal intestinal mucosa. The researchers speculate that the the. CTBPl related with the occurrence of colorectal cancer in about 85%. it may become a new target molecules for colorectal cancer. CTBPl initially were identified based on the specific binding properties of the C-terminus with the adenovirus E1 A and named. It is a protein having dehydrogenase molecules. can be used as a transcriptional repressor sub-Delta-EFl synergistic molecular regulation of intracellular gene transcription process. In recent years. the study found. CTBPl can inhibit the expression of pro-apoptotic genes. which can promote cell survival or eternal life. A growing number of studies suggest that. CTBPl may be associated with oncogenesis. But about CTBPl expression in human malignancies. so far. in addition to the above-mentioned study. not yet other reports. (D) P53 gene of wild-type p53 gene at 17p chromosome has an important tumor suppressor function on encoding P53 phosphophoryn; to a wild-type p53 in many apoptosis signaling pathway plays a very important role. including film apoptosis signal. mitochondrial apoptotic pathway. as well as in the nucleus affects transcription and expression of apoptosis-related factors. Wild-type P53 gene inactivation into mutant P53 gene by deletion or mutation. mutant p53 gene has tumorigenic effects. Detection of cell growth and the balance will not be able to carry out. and the body cells start to accumulate mutations. eventually leading to the occurrence of cancer. P53 gene mutations and deletions in leukemia. osteosarcoma. lung cancer and colorectal cancer. (E) PTEN gene PTEN is a tumor suppressor gene. After research showed that: colorectal mucosa adjacent to cancer. colon adenoma and normal colon mucosa PTEN protein positive expression rate was 59.1%. 76.9%. 76.4%. and 100%. respectively. No colon expression was significantly lower than the non-cancer group (P Media Recommended Satisfaction guaranteed,or money back.<